Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Comparing the Survival Analysis of Two or More Groups

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and Cox...

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

Cancer-Critical Genes II: Tumor Suppressor Genes

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The role of contrast-enhanced mammography in the preoperative evaluation of invasive lobular carcinoma of the breast.

Clinical radiology·2024

Same author

Hot crystals of thermo-responsive particles with temperature dependent diameter in the presence of a temperature gradient.

The Journal of chemical physics·2023

Same author

Histology of Convergent Probing Appendages in Mormyridae.

Integrative organismal biology (Oxford, England)·2023

Same author

Conformational fluctuations in the molten globule state of α-lactalbumin.

Physical chemistry chemical physics : PCCP·2022

Same author

Viscoelastic response of fluid trapped between two dissimilar van der Waals surfaces.

Journal of physics. Condensed matter : an Institute of Physics journal·2022

Same author

A long-range order in a thermally driven system with temperature-dependent interactions.

Soft matter·2022

Search research articles

Related Experiment Video

Updated: Jul 17, 2026

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

NHSBSP type 1 interval cancers: a scientifically valid grouping?

G J R Porter¹, A J Evans, H C Burrell

¹Nottingham Breast Institute, City Hospital, Nottingham, UK. garethporter@doctors.org.uk

Clinical Radiology

|February 13, 2007

Summary

The new National Health Service Breast Screening Programme (NHSBSP) type 1 interval breast cancers are diverse in pathology but show no survival differences between subgroups. Further analysis of these interval cancers is warranted.

Related Experiment Videos

Last Updated: Jul 17, 2026

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

Area of Science:

Oncology
Pathology
Public Health

Background:

The National Health Service Breast Screening Programme (NHSBSP) introduced a new classification for type 1 interval breast cancers.
Previously, interval cancers were categorized as occult, unclassified, or true interval cancers.
Understanding the heterogeneity within type 1 interval cancers is crucial for accurate prognosis.

Purpose of the Study:

To compare pathological features and survival rates of type 1 interval breast cancers within the new NHSBSP classification.
To determine if occult, unclassified, and true interval cancers differ significantly in their characteristics and patient outcomes.
To evaluate the clinical significance of the new type 1 interval cancer grouping.

Main Methods:

Analysis of prognostic pathological features (grade, lymph node stage, size, vascular invasion, oestrogen receptor status, histological type) for 428 type 1 interval invasive breast cancers.
Subgroup analysis comparing occult, unclassified, and true interval cancers.
Survival data was analyzed in conjunction with pathological features.

Main Results:

Occult cancers exhibited significantly lower grade, smaller size, and a higher frequency of lobular type compared to other type 1 interval cancers.
No significant differences in pathological features were observed between unclassified tumours and other type 1 tumours.
Despite pathological variations, no significant survival difference was found among the different type 1 interval cancer subgroups (p=0.12).

Conclusions:

The NHSBSP type 1 interval cancer classification encompasses a heterogeneous group of tumours with distinct pathological features.
The observed pathological differences among type 1 interval cancer subgroups do not translate into significant survival disparities.
The clinical implications of classifying type 1 interval cancers require further investigation given the lack of survival differences.